|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastroenterologist perceptions of faecal microbiota transplantation显示文摘AIM: To explore gastroenterologist perceptions towards and experience with faecal microbiota transplantation(FMT).METHODS: A questionnaire survey consisting of 17 questions was created to assess gastroenterologists' attitude towards and experience with FMT. This was anonymously distributed in hard copy format amongst attendees at gastroenterology meetings in Australia between October 2013 and April 2014. Basic descriptive statistical analyses were performed.RESULTS: Fifty-two clinicians participated. Twenty one percent had previously referred patients for FMT,8% more than once. Ninety percent would refer patients with Clostridium difficile infection(CDI) for FMT if easily available,37% for ulcerative colitis,13% for Crohn's disease and 6% for irritable bowel syndrome. Six percent would not refer any indication,including recurrent CDI. Eighty-six percent would enroll patients in FMT clinical trials. Thirty-seven percent considered the optimal mode of FMT administration transcolonoscopic,17% nasoduodenal,13% enema and 8% oral capsule. The greatest concerns regarding FMT were: 42% lack of evidence,12% infection risk,10% non infectious adverse effects/lack of safety data,10% aesthetic,10% lack of efficacy,4% disease exacerbation,and 2% inappropriate use; 6% had no concerns. Seventy seven percent believed there is a lack of accessibility while 52% had an interest in learning how to provide FMT. Only 6% offered FMT at their institution.CONCLUSION: Despite general enthusiasm,most gastroenterologists have limited experience with,or access to,FMT. The greatest concerns were lack of supportive evidence and safety issues. However a significant proportion would refer indications other than CDI for FMT despite insufficient evidence. These data provide guidance on where education and training are required. | Sudarshan Paramsothy Alissa J Walsh Thomas Borody Douglas Samuel Johan van den Bogaerde Rupert WL Leong Susan Connor Watson Ng Hazel M Mitchell Nadeem O Kaakoush Michael A Kamm | 2015 | World Journal of Gastroenterology2015，21，38： | 5 |
| 2 | Epidemiology of inflammatory bowel disease in South America: A systematic review显示文摘BACKGROUND The worldwide epidemiology of inflammatory bowel disease(IBD)is rapidly changing.Increasing Crohn’s disease(CD)and ulcerative colitis(UC)incidence and prevalence have been recorded in developing regions such as Asia,Africa and Eastern Europe where it was previously thought to be uncommon.Whether this is also the case in South America is not well known.Demonstration that developing regions worldwide have increasing IBD incidence would indicate that environmental change plays a significant role in the development of IBD.AIM To report the incidence,prevalence and disease characteristics of CD and UC within the South American continent.METHODS A systematic review was conducted by searching published studies in major international and regional databases(MEDLINE,EMBASE and Scopus)between January 1990 and December 2018.Outcomes considered were incidence,prevalence,phenotype,environmental and genetic factors,ethnicity and gender.A pair of independent reviewers screened and reviewed all identified articles.RESULTS One hundred and sixty two citations were initially retrieved with 18 studies included in this systematic review.The majority of included studies were from Brazil(n=13,72%).The incidence of UC ranged from 4.3-5.3/100000 personyears whilst the incidence of CD ranged from 0.74-3.5/100000 person-years.Prevalence ranged from 15.0-24.1/100000 inhabitants for UC and from 2.4-14.1/100000 inhabitants for CD.The incidence and prevalence of both UC and CD has increased significantly in Brazil over the past 21 years.Pancolitis was the most common disease distribution in patients with UC whilst colonic involvement was the most common distribution in CD.People residing in urban areas were at higher risk of developing both CD and UC.CONCLUSION The IBD burden in South America is increasing at a rate possibly even greater than other developing regions around the world.There is a paucity of highquality epidemiological studies and further robust and representative data are required to further explore modifiable risk factors and disease phenotypes. | Sriharan Selvaratnam Santiago Gullino Lisa Shim Eric Lee Alice Lee Sudarshan Paramsothy Rupert W Leong | 2019 | World Journal of Gastroenterology2019，25，47： | 5 |
| 3 | Biochar can Increase Chinese Cabbage(Brassica oleracea L.)Yield,Decrease Nitrogen and Phosphorus Leaching Losses in Intensive Vegetable Soil显示文摘There are few evidences on the effect of biochar on vegetable yield,nitrogen(N)and phosphorus(P)leaching losses under intensive vegetable production soil.The current field plot scale study evaluated responses of Chinese cabbage(Brassica oleracea L.)yield,N and P leaching losses using five N treatments of common N application rate according to local farmers’practice(N100%),reducing 20%or 40%N fertilizer(N80%and N60%),and reducing 40%N fertilizer but incorporating 10 or 20 t/ha biochar(N60%+BC10 and N60%+BC20).Results showed that N80%and N60%decreased both the cabbage economic and leaf yields by 6.8%-36.3%and 27.4%-37.7%,respectively.Incorporation of biochar with reduced N fertilizer rates improved the cabbage yield,in particular the N60%+BC20 matched the yield that observed in N100%treatment.Enhanced N and P uptake capacities of cabbage shoot probably contributed the higher vegetable production under both biochar amendment schemes.Biochar application mitigated the NH_(4)^(+)-N and total P leaching losses by 20%-30%and 29%-32%,respectively,compared with their counterpart treatment N60%.Nevertheless,biochar exerted no influence on the NO_(3)^(-)-N leaching.In addition,soil organic matter content was recorded with 7.4%-28.7%higher following 10-20 t/ha biochar application.In conclusion,biochar application can increase economic yield of cabbage via increasing N and P use efficiency,decrease N and P leaching losses,and improve soil quality in an intensive vegetable production system. | Haijun Sun Paramsothy Jeyakumar Hongdong Xiao Xuewen Li Jiayou Liu Min Yu Prabal Bir Jung Rana Weiming Shi | 2022 | Phyton-International Journal of Experimental Botany2022，91，1： | 3 |
| 4 | Fecal Microbiota Transplantation: Indications, Methods, Evidence, and Future Directions显示文摘 | Thomas J. Borody Sudarshan Paramsothy Gaurav Agrawal | 2013 | Current Gastroenterology Reports2013，，8： | 3 |
| 5 | Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease显示文摘BACKGROUND Tumor necrosis factor-alpha inhibitors,including infliximab and adalimumab,are effective medical treatments for perianal fistulising Crohn’s disease(CD),but not all patients achieve fistula healing.AIM To determine the correlation between perianal fistula healing and closure with infliximab and adalimumab trough levels.METHODS In this multicentre retrospective study conducted across four tertiary inflammatory bowel disease centres in Australia,we identified CD patients with perianal fistulae on maintenance infliximab or adalimumab who had a trough level within twelve weeks of clinical assessment.Data collected included demographics,serum infliximab and adalimumab trough levels(mg/L)within 12 wk before or after their most recent clinical assessment and concomitant medical or surgical therapy.The primary outcome was fistula healing,defined as cessation in fistula drainage.The secondary outcome was fistula closure,defined as healing and closure of all external fistula openings.Differences between patients who did or did not achieve fistula healing were compared using the chi-square test,t test or Mann-Whitney U test.RESULTS One hundred and fourteen patients(66 infliximab,48 adalimumab)were included.Forty-eight(72.7%)patients on maintenance infliximab achieved fistula healing and 18(27.3%)achieved fistula closure.Thirty-seven(77%)patients on maintenance adalimumab achieved fistula healing and 17(35.4%)achieved fistula closure.Patients who achieved fistula healing had significantly higher infliximab and adalimumab trough levels than patients who did not[infliximab:6.4(3.8-9.5)vs 3.0(0.3-6.2)mg/L,P=0.003;adalimumab:9.2(6.5-12.0)vs 5.4(2.5-8.3)mg/L,P=0.004].For patients on infliximab,fistula healing was associated with lower rates of detectable anti-infliximab antibodies and younger age.For patients on adalimumab,fistula healing was associated with higher rates of combination therapy with an immunomodulator.Serum trough levels for patients with and without fistula closure were not significantly different for infliximab[6.9(4.3-10.2)vs 5.5(2.5-8.3)mg/L,P=0.105]or adalimumab[10.0(6.6-12.0)vs 7.8(4.2-10.0)mg/L,P=0.083].CONCLUSION Higher maintenance infliximab and adalimumab trough levels are associated with perianal fistula healing in CD. | Bonita Gu Kavya Venkatesh Astrid-Jane Williams Watson Ng Crispin Corte Ali Gholamrezaei Simon Ghaly Wei Xuan Sudarshan Paramsothy Susan Connor | 2022 | World Journal of Gastroenterology2022，28，23： | 2 |
| 6 | Serumcreatinine is an inadequate screening test for renal failure in elder-ly patients显示文摘 | SWEDKO P J CLARK H D PARAMSOTHY K | 2003 | Arch Intern Med2003，163，3： | 1 |
| 7 | Fecal mi- crobiota transplantation : indications, methods, evidence, and future directions 显示文摘 | Borody T J Paramsothy S Agrawal G | 2013 | Curr Gastro- enterol Rep2013，15，8： | 1 |
| 8 | Therapeutic faecal microbiota transplantation: current status and future developments显示文摘 | Thomas J. Borody Lawrence J. Brandt Sudarshan Paramsothy | 2014 | Current Opinion in Gastroenterology2014，，1： | 1 |
| 9 | Addition of CNTs to enhance tensile/compressive response of magnesium alloy ZK60A显示文摘 | M. Paramsothy J. Chan R. Kwok M. Gupta | 2010 | Composites Part A2010，，2： | 1 |
| 10 | Addition of CNTs to enhance tensile/compressive response of magnesium ahoy ZK60A显示文摘 | PARAMSOTHY M CHAN J KWOK R | 2011 | Composites2011，42，2： | 1 |
| 11 | Route of delivery and neonatal birth trauma显示文摘 | Moczygemba CK Paramsothy P Meille S | 2010 | Am J Obstet Gynecol2010，202，4： | 1 |
| 12 | In- fluence of nano-sized carbon nanotube reinforcements on tensile deformation, cyclic fatigue, and final fracture behavior of a Mag- nesium alloy 显示文摘 | SRIVATSAN T S GODBOLE C PARAMSOTHY M | 2012 | Journal of Materials Science2012，47，8： | 1 |
| 13 | Using Mg and Mg-nano Al2O3 concentric alternating macroring material design to enhance the properties of magnesium显示文摘 | WONG J C PARAMSOTHY M GUPTA M | 2009 | Composites Science and Technology2009，69，3： | 1 |
| 14 | Addition of CNTs to enhance tensile/compressive response of magnesium alloy ZK60A显示文摘 | Paramsothy M Chan J Kwok R | 2011 | Composite2011，42，： | 1 |
| 15 | Influence of nano-sized carbon nanotube reinforcements on tensile deformation,cyclic fatigue,and final fracture behavior of a magnesium alloy显示文摘 | T.S Srivatsan C Godbole M Paramsothy M Gupta | | 0，，47： | 1 |
| 16 | Axonal neuregulin 1 is a rate limiting but not essential factor for nerve remyelination显示文摘 | Fricker FR Antunes-Martins A Galino J Paramsothy R La Russa F Perkins J Goldberg R Brelstaff J Zhu N McMahon SB Orengo C Garratt AN Birch-meier C Bennett DL | | 0，，： | 1 |
| 17 | Serum ereatinine is aninadequate screening test for renal failure in elderly patients显示文摘 | SWEDKO P J CLARK H D PARAMSOTHY K | 2003 | Arch Intern Med2003，163，3： | 1 |
| 18 | Adding Carbon Nanotubes and Integrating with AA5052 Aluminium Alloy Core to Simultaneously Enhance Stiffness,Strength and Failure Strain of AZ31 Magnesium Alloy显示文摘 | Paramsothy M Hassan S F Srikanth N | 2009 | Composites Part A:Applied Science and Manufacturing2009，40，9： | 1 |
| 19 | Using integrated hybrid (Al<ce:hsp sp='0.25'/>+<ce:hsp sp='0.25'/>CNT) reinforcement to simultaneously enhance strength and ductility of magnesium显示文摘 | M.K. Habibi M. Paramsothy A.M.S. Hamouda M. Gupta | 2011 | Composites Science and Technology2011，，5： | 1 |
| 20 | Association of combinations of lipid parameters with carotid intima-media thickness and coronary artery Calcium in the Mesa (Multi-Ethnic Study of Atherosclerosis)显示文摘 | Paramsothy P Knopp RH Bertoni AG | | 0，，13： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员